Chargement en cours...
Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
RATIONALE: Within a rapidly expanding therapeutic armamentarium, the combination of everolimus (Eve) plus exemestane (Exe) utility needs to be reinstated in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). PATIENT CONCERNS: We...
Enregistré dans:
| Publié dans: | Medicine (Baltimore) |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Wolters Kluwer Health
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7402792/ https://ncbi.nlm.nih.gov/pubmed/32756099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000021211 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|